Background
Tezepelumab is a first-in-class human monoclonal antibody that binds to TSLP, thus inhibiting its interaction with TSLP receptor complex. Tezepelumab given as an add-on-therapy to patients with severe uncontrolled asthma has shown safety, tolerability and efficacy. Several trials are evaluating the long-term safety and the efficacy of tezepelumab in adults and adolescents with severe uncontrolled asthma.• Thymic Stromal Lymphopoietin (TSLP), Its Isoforms and the Interplay with the Epithelium in Allergy and Asthma., PMID:37628907• Thymic stromal lymphopoietin: its role and potential as a therapeutic target in asthma., PMID:32567399• Targeting interleukin-33 and thymic stromal lymphopoietin pathways for novel pulmonary therapeutics in asthma and COPD., PMID:36697211• Role of thymic stromal lymphopoietin in allergy and beyond., PMID:35650271• IL-31-generating network in atopic dermatitis comprising macrophages, basophils, thymic stromal lymphopoietin, and periostin., PMID:36410530• Serum thymic stromal lymphopoietin (TSLP) levels in atopic dermatitis patients: a systematic review and meta-analysis., PMID:37515689• Thymic Stromal Lymphopoietin and Tezepelumab in Airway Diseases: From Physiological Role to Target Therapy., PMID:38892164• Investigational thymic stromal lymphopoietin inhibitors for the treatment of asthma: a systematic review., PMID:38206116• Pathogenesis of allergic diseases and implications for therapeutic interventions., PMID:36964157• Thymic stromal lymphopoietin (TSLP) is a substrate for tryptase in patients with mastocytosis., PMID:37500310